ArticlePharmacoEconomics2023

Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2- Metastatic Breast Cancer in Postmenopausal Women in the USA.

Prajakta P Masurkar et al.PubMed ↗Publisher ↗

No numbers read from the abstract.